Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues

Neurobiology of Disease

Volumn 48, Issue 2, 2012, Pages 212-221

  Manfredsson, Fredric P ^a   Bloom, David C ^b   Mandel, Ronald J ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Adenovirus; Central nervous system; Ecdysone; In vivo gene transfer; Lentivirus; Mifepristone; Tetracycline; Transcriptional regulation; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; APTAMER; CELL PROTEIN; ECDYSONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; MIFEPRISTONE; PARVOVIRUS VECTOR; PRODRUG; PROTEIN P16; RAPAMYCIN; RIBOZYME; VIRUS VECTOR;

ALZHEIMER DISEASE; BIOMECHANICS; GENE CONTROL; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; GENE PRODUCT; GENE THERAPY; GENE TRANSFER; GENETIC REGULATION; GENETIC STABILITY; HERPES SIMPLEX VIRUS 1; HUMAN; IN VIVO STUDY; LAC GENE; NEUROLOGIC DISEASE; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; OPERON; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; REPRESSOR GENE; REVIEW; RIBOSWITCH; TET OPERON; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NERVOUS SYSTEM DISEASES; PROMOTER REGIONS, GENETIC; SMALL MOLECULE LIBRARIES; TRANSCRIPTION, GENETIC; TRANSGENES; VIRUSES;

EID: 84865567760     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.001     Document Type: Review

References (90)

1. Adamantidis A.R., et al. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007, 450:420-424.
2. Auslander S., et al. A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression. Mol. Biosyst. 2010, 6:807-814.
3. Banaszynski L.A., et al. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 2006, 126:995-1004.
4. Banaszynski L.A., et al. Chemical control of protein stability and function in living mice. Nat. Med. 2008, 14:1123-1127.
5. Barza M., et al. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob. Agents Chemother. 1975, 8:713-720.
6. Bass C.E., et al. Optogenetic control of striatal dopamine release in rats. J. Neurochem. 2010, 114:1344-1352.
7. Benzekhroufa K., et al. Targeting central serotonergic neurons with lentiviral vectors based on a transcriptional amplification strategy. Gene Ther. 2009, 16:681-688.
8. Berman B., et al. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc.) 2007, 43:27-34.
9. Blasey C.M., et al. Efficacy and safety of mifepristone for the treatment of psychotic depression. J. Clin. Psychopharmacol. 2011, 31:436-440.
10. Blasey C.M., et al. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Contemp. Clin. Trials 2009, 30:284-288.
11. Burcin M.M., et al. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:355-360.
12. Cao L., et al. Molecular therapy of obesity and diabetes by a physiological autoregulatory approach. Nat. Med. 2009, 15:447-454.
13. Caron L., et al. The Lac repressor provides a reversible gene expression system in undifferentiated and differentiated embryonic stem cell. Cell. Mol. Life Sci. 2005, 62:1605-1612.
14. Chang Q., et al. Molecular, cellular, and behavioral characterization of a tetracycline (Tet)-regulated rAAV vector for human aromatic amino acid decarboxylase (hAADC) in a rat model of Parkinson's disease (PD). Mol. Ther. 2008, 16:S264.
15. Chojnacki A.K., et al. Identity crisis for adult periventricular neural stem cells: subventricular zone astrocytes, ependymal cells or both?. Nat. Rev. Neurosci. 2009, 10:153-163.
16. Christopherson K.S., et al. Ecdysteroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone receptor and chimeric transactivators. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6314-6318.
17. Chtarto A., et al. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther. 2003, 10:84-94.
18. Chtarto A., et al. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp. Neurol. 2007, 204:387-399.
19. Cloughesy T.F., et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5:e8.
20. Cronin C.A., et al. The lac operator-repressor system is functional in the mouse. Genes Dev. 2001, 15:1506-1517.
21. Culler S.J., et al. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 2010, 330:1251-1255.
22. Diester I., et al. An optogenetic toolbox designed for primates. Nat. Neurosci. 2011, 14:387-397.
23. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
24. Fiala A., et al. Optogenetic approaches in neuroscience. Curr. Biol. 2010, 20:R897-R903.
25. Forsayeth J.R., Bankiewicz K.S. AAV9: over the fence and into the woods. Mol. Ther. 2011, 19:1006-1007.
26. Georgievska B., et al. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum. Gene Ther. 2004, 15:934-944.
27. Golde T.E., et al. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011, 69:203-213.
28. Gordon L., et al. Detection of herpes simplex virus (types 1 and 2) and human herpesvirus 6 DNA in human brain tissue by polymerase chain reaction. Clin. Diagn. Virol. 1996, 6:33-40.
29. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:5547-5551.
30. Gross C., et al. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv. Ther. 2009, 26:959-969.
31. Haberman R.P., McCown T.J. Regulation of gene expression in adeno-associated virus vectors in the brain. Methods 2002, 28:219-226.
32. Hadaczek P., et al. Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One 2011, 6:e27728.
33. Ho S.N., et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature 1996, 382:822-826.
34. Hou S.T., et al. A novel adenoviral vector-mediated neuronal selective gene expression in neonatal mouse brain in response to hypoxia. Neurosci. Lett. 2007, 419:23-27.
35. Hu M.C., Davidson N. The inducible lac operator-repressor system is functional in mammalian cells. Cell 1987, 48:555-566.
36. Hurttila H., et al. Oxidative stress-inducible lentiviral vectors for gene therapy. Gene Ther. 2008, 15:1271-1279.
37. Hwang D.Y., et al. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. Hum. Gene Ther. 2001, 12:1731-1740.
38. Iwamoto M., et al. A general chemical method to regulate protein stability in the mammalian central nervous system. Chem. Biol. 2010, 17:981-988.
39. Jakobsson J., et al. Targeted transgene expression in rat brain using lentiviral vectors. J. Neurosci. Res. 2003, 73:876-885.
40. Jakobsson J., et al. Lesion-dependent regulation of transgene expression in the rat brain using a human glial fibrillary acidic protein-lentiviral vector. Eur. J. Neurosci. 2004, 19:761-765.
41. Karatas H., et al. Investigation of HSV-1, HSV-2, CMV, HHV-6 and HHV-8 DNA by real-time PCR in surgical resection materials of epilepsy patients with mesial temporal lobe sclerosis. J. Neurol. Sci. 2008, 264:151-156.
42. Lamartina S., et al. Construction of an rtTA2(s)-m2/tts(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. Mol. Ther. 2003, 7:271-280.
43. Latta-Mahieu M., et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum. Gene Ther. 2002, 13:1611-1620.
44. Lewin A.S., Hauswirth W.W. Ribozyme gene therapy: applications for molecular medicine. Trends Mol. Med. 2001, 7:221-228.
45. LeWitt P.A., et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011, 10:309-319.
46. Liu J., et al. Identification of cell type-specific promoter elements associated with the rat tyrosine hydroxylase gene using transgenic founder analysis. Brain Res. Mol. Brain Res. 1997, 50:33-42.
47. Liu Y., et al. A genomic screen for activators of the antioxidant response element. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5205-5210.
48. Liu Y., et al. Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea. Mol. Ther. 2008, 16:474-480.
49. Loew R., et al. Improved Tet-responsive promoters with minimized background expression. BMC Biotechnol. 2010, 10:81.
50. Lonergan T., et al. Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression. Physiol. Genomics 2005, 20:165-172.
51. Lowenstein P.R., et al. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr. Gene Ther. 2007, 7:347-360.
52. Maguire A.M., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 2008, 358:2240-2248.
53. Mandel R.J., et al. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol. Ther. 2006, 13:463-483.
54. Manfredsson F.P., et al. Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol. Ther. 2009, 17:1857-1867.
55. Manfredsson F.P., et al. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr. Gene Ther. 2009, 9:375-388.
56. Manfredsson F.P., et al. AAV9: a potential blood-brain barrier buster. Mol. Ther. 2009, 17:403-405.
57. Manfredsson F.P., et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol. Ther. 2009, 17:980-991.
58. Mansuy I.M., Bujard H. Tetracycline-regulated gene expression in the brain. Curr. Opin. Neurobiol. 2000, 10:593-596.
59. Marks W.J., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, 9:1164-1172.
60. Marks W.J., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
61. Min N., et al. 5' Upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice. Brain Res. Mol. Brain Res. 1994, 27:281-289.
62. Nathwani A.C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 2011, 365:2357-2365.
63. No D., et al. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3346-3351.
64. Nordstrom J.L. The antiprogestin-dependent GeneSwitch system for regulated gene therapy. Steroids 2003, 68:1085-1094.
65. Oh M.S., et al. Expression of transgenes in midbrain dopamine neurons using the tyrosine hydroxylase promoter. Gene Ther. 2009, 16:437-440.
66. Oligino T., et al. Drug inducible transgene expression in brain using a herpes simplex virus vector. Gene Ther. 1998, 5:491-496.
67. Peel A.L., et al. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 1997, 4:16-24.
68. Pollock R., et al. Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13221-13226.
69. Rivera V.M., et al. A humanized system for pharmacologic control of gene expression. Nat. Med. 1996, 2:1028-1032.
70. Rivera V.M., et al. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science 2000, 287:826-830.
71. Rock D.L., Fraser N.W. Detection of HSV-1 genome in central nervous system of latently infected mice. Nature 1983, 302:523-525.
72. Shen F., et al. Adeno-associated viral-vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice. Stroke 2006, 37:2601-2606.
73. Suess B., et al. Conditional gene expression by controlling translation with tetracycline-binding aptamers. Nucleic Acids Res. 2003, 31:1853-1858.
74. Svedhem A., Iwarson S. Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment. J. Antimicrob. Chemother. 1979, 5:717-720.
75. Szulc J., Aebischer P. Conditional gene expression and knockdown using lentivirus vectors encoding shRNA. Methods Mol. Biol. 2008, 434:291-309.
76. Szymanski P., et al. Development and characterization of a synthetic promoter for selective expression in proliferating endothelial cells. J. Gene Med. 2006, 8:514-523.
77. Szymanski P., et al. Development and validation of a robust and versatile one-plasmid regulated gene expression system. Mol. Ther. 2007, 15:1340-1347.
78. Tang Y., et al. Vigilant vectors: adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases. Methods 2002, 28:259-266.
79. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
80. Vaillancourt P., Felts K.A. Retroviral delivery of the ecdysone-regulatable gene expression system. Biotechnol. Prog. 2003, 19:1750-1755.
81. Wang Y., et al. A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8180-8184.
82. Warren K.G., et al. Isolation of Herpes simplex virus from human trigeminal ganglia, including ganglia from one patient with multiple sclerosis. Lancet 1977, 2:637-639.
83. Williams J.C., et al. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Mol. Ther. 2001, 4:593-602.
84. Xie J., et al. A comparative study examining the cytotoxicity of inducible gene expression system ligands in different cell types. Toxicol. In Vitro 2008, 22:261-266.
85. Xie J., et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 2011, 19:526-535.
86. Xiong W., et al. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol. Ther. 2008, 16:343-351.
87. Xu F., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
88. Yang X., et al. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J. Gene Med. 2009, 11:899-912.
89. Ye X., et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999, 283:88-91.
90. Yen L., et al. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 2004, 431:471-476.